RA | Jotup

Safal Partners Awarded US DOL Contract to Expand Cybersecurity Apprenticeship

Retrieved on:

Tuesday, August 8, 2023

Workforce, White House, RA, Safal, Education, U.S. Department of Defense Strategy for Operating in Cyberspace, Disability, Woman, Multimedia, DOL, Veteran, Public sector, Administration, U.S. Department of Labor, Office of Inspector General, Occupation, United Nations Industrial Development Organization, Construction, Nursing, Financial adviser

HOUSTON, Aug. 8, 2023 /PRNewswire/ -- Safal Partners, a national management consulting firm and recognized leader in apprenticeship, has been awarded a contract by the U.S. Department of Labor (DOL) to serve as the National Industry Intermediary expanding registered apprenticeship (RA) for cybersecurity occupations.

Key Points:

HOUSTON, Aug. 8, 2023 /PRNewswire/ -- Safal Partners, a national management consulting firm and recognized leader in apprenticeship, has been awarded a contract by the U.S. Department of Labor (DOL) to serve as the National Industry Intermediary expanding registered apprenticeship (RA) for cybersecurity occupations.
Safal Partners, the National Industry Intermediary expanding registered apprenticeship for cybersecurity occupations.
"Safal is proud to lead apprenticeship expansion work with DOL as part of the Administration's NCWES and create a stronger, more diverse cybersecurity talent pipeline," said Mukta Pandit, Safal Partners President.
The DOL contract announcement builds on the firm's successful execution of a previous DOL cybersecurity apprenticeship contract through which Safal supported the registration of more than 1,400 new apprentices in cyber and tech occupations in two years.

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

Monday, August 7, 2023

Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023

Key Points:

Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.
She had extensive experience at Bristol-Meyers Squibb where she led teams that advanced more than 20 compounds into clinical development.
Among her prior roles includes serving as Principia’s chief medical officer from 2018 until the Sanofi acquisition in September 2020.
Cash, cash equivalents and investments totaled $488.7 million as of June 30, 2023, compared to $584.2 million as of December 31, 2022, for a decrease of $95.5 million.

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on:

Monday, August 7, 2023

WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2023 and provided a corporate update.

Key Points:

Aclaris continues to expect topline data in the fourth quarter of 2023.
Aclaris continues to expect topline data in the second half of 2023.
Net loss was $29.6 million for the second quarter of 2023 compared to $20.5 million for the second quarter of 2022.
Total revenue was $1.9 million for the second quarter of 2023 compared to $1.5 million for the second quarter of 2022.

IGM Biosciences Announces Second Quarter 2023 Financial Results

Retrieved on:

Thursday, August 3, 2023

MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended June 30, 2023.

Key Points:

MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended June 30, 2023.
Collaboration Revenue: For the second quarter of 2023, collaboration revenues were $0.4 million, compared to $0.4 million for the same period in 2022.
Research and Development (R&D) Expenses: For the second quarter of 2023, R&D expenses were $55.7 million, compared to $47.2 million for the same period in 2022.
General and Administrative (G&A) Expenses: For the second quarter of 2023, G&A expenses were $13.0 million, compared to $12.4 million for the same period in 2022.

Galapagos announces first half-year 2023 financial results

Retrieved on:

Thursday, August 3, 2023

Exercise, Filgotinib, RA, CET, CD19, JAK, CTA, SLE, Burn, Gilead, UC, Patient, Multiple myeloma, TYK2, Hematology, Drug discovery, Growth, IND, Arthritis, BCMA, Cryptocurrency, Pharmaceutical industry

R&D expenditure in the first six months of 2023 amounted to €211.9 million, compared to €249.5 million for the first six months of 2022.

Key Points:

R&D expenditure in the first six months of 2023 amounted to €211.9 million, compared to €249.5 million for the first six months of 2022.
Net financial income in the first six months of 2023 amounted to €30.6 million, compared to net financial income of €67.7 million for the first six months of 2022.
Current financial investments and cash and cash equivalents totaled €3,874.9 million on 30 June 2023, as compared to €4,094.1 million on 31 December 2022.
Galapagos’ financial report for the first six months ended 30 June 2023, including details of the unaudited consolidated results, is accessible on the financial reports section of our website .

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

Retrieved on:

Monday, July 31, 2023

“The Company’s progress is clear, and the impact of the changes we have made will continue to move us forward.

Key Points:

“The Company’s progress is clear, and the impact of the changes we have made will continue to move us forward.
(Fix) Selling, general and administrative expenses were down 36% in the first quarter of 2023, compared to the same period in 2022.
(Fund/Propel) The Company launched its Strategic Partnership Initiative focused on developing long-term licensing revenue opportunities in Q3 2023.
“Our journey and our focus is to advance innovative technology to market, and to deliver value to our stockholders."

REVASUM (ASX: RVS) secures a Letter of Intent to purchase a 6EZ silicon carbide CMP system from SENIC, a leading silicon carbide substrate manufacturing technology company in Cheonan, South Korea

Retrieved on:

Thursday, July 27, 2023

Valašská Senice, CMP, Silicon carbide, Silicon, Partnership, TTV, RA, SAN, MOSFET, Ceramic

The recent release of the 6EZ's 200mm conversion kit will enable the tool to support 150mm and 200mm SiC substrate manufacturing at the Senic facility in Cheonan, South Korea.

Key Points:

The recent release of the 6EZ's 200mm conversion kit will enable the tool to support 150mm and 200mm SiC substrate manufacturing at the Senic facility in Cheonan, South Korea.
The 6EZ CMP system was developed with Revasum's 7AF-HMG SiC grinder to remove sub-surface damage from the grind process.
The 6EZ provides minimal total thickness variation (TTV) across the wafer and surface roughness (RA) to be on the order of 1.5 Angstroms.
With the 6EZ already having proved itself in silicon carbide substrate manufacturing, we believe the 6EZ system is the best option for Senic as we increase our production to meet the global industry demands."

REVASUM (ASX: RVS) secures a Letter of Intent to purchase a 6EZ silicon carbide CMP system from SENIC, a leading silicon carbide substrate manufacturing technology company in Cheonan, South Korea

Retrieved on:

Thursday, July 27, 2023

Partnership, RA, Valašská Senice, TTV, ASX, LOI, CMP, Silicon carbide, SAN, Silicon, MOSFET, Ceramic

REVASUM (ASX:RVS) secures LOI to purchase a 6EZ CMP system from SENIC, a leading S. Korean SiC substrate mfg company

Key Points:

REVASUM (ASX:RVS) secures LOI to purchase a 6EZ CMP system from SENIC, a leading S. Korean SiC substrate mfg company
The recent release of the 6EZ's 200mm conversion kit will enable the tool to support 150mm and 200mm SiC substrate manufacturing at the Senic facility in Cheonan, South Korea.
The 6EZ CMP system was developed with Revasum's 7AF-HMG SiC grinder to remove sub-surface damage from the grind process.
The 6EZ provides minimal total thickness variation (TTV) across the wafer and surface roughness (RA) to be on the order of 1.5 Angstroms.
With the 6EZ already having proved itself in silicon carbide substrate manufacturing, we believe the 6EZ system is the best option for Senic as we increase our production to meet the global industry demands."

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Retrieved on:

Wednesday, July 26, 2023

RA, Marketing, Drug discovery, New Drug Application, NDA, ASX, Inflammation, Investigational New Drug, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Safety, Food, Cannabidiol, Rheumatoid arthritis, Pharmaceutical industry, Medical device

IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including RA.

Key Points:

IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including RA.
Incannex submitted a pre-IND meeting package to the FDA in June 2023.
In the written correspondence, FDA provided valuable, multidisciplinary feedback on the proposed clinical development of IHL-675A.
Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Feedback received from the FDA in the pre-IND meeting is highly valuable for the continued development of IHL-675A for treatment of rheumatoid arthritis.

RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal

Retrieved on:

Tuesday, July 25, 2023

Lupus, Society, RA, Peking Union Medical College Hospital, Xerostomia, Hope, Research, SLE, Rheumatoid arthritis, Patient, Oxford University Press, SS, PSS, Saliva, Immunology, EULAR, Safety, Pharmaceutical industry, Rheumatology

Rheumatology is the official journal of the British Society for Rheumatology which is published by Oxford University Press.

Key Points:

Rheumatology is the official journal of the British Society for Rheumatology which is published by Oxford University Press.
The journal is currently included in 27 international databases and is a top journal in this field with an impact factor of 7.046 in 2021.
As a new drug with significant potential, telitacicept Phase II clinical study data has been published in top international journals, which is major proof of our research and development capabilities.
Telitacicept, a novel fully human TACI-Fc fusion protein, shows promise in inhibiting B cell maturation and reducing autoantibody production, offering significant potential disease activity control.